Thermo Fisher to acquire Brammer Bio in $1.7B gene-therapy deal
Thermo Fisher Scientific is buying Brammer Bio for $1.7B, expanding the company’s presence in the field of gene therapy.
Brammer Bio, owned by Ampersand Capital Partners, provides pharmaceutical companies developing gene therapies and gene-modified cell therapies with outsourced research and drugmaking services.
